Ubs Oconnor LLC Inozyme Pharma, Inc. Transaction History

Ubs Oconnor LLC

$1.72 Billion
Q2 2024

A detailed history of Ubs Oconnor LLC transactions in Inozyme Pharma, Inc. stock. As of the latest transaction made, Ubs Oconnor LLC holds 205,218 shares of INZY stock, worth $1.05 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares

205,218

Holding current value

$1.05 Million

% of portfolio

0.05%

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$4.33 - $7.31 $95,260 - $160,820	22,000 Added 12.01%	205,218 $915,000
Q1 2024 May 15, 2024	SELL	$4.14 - $7.66 $255,479 - $472,698	-61,710 Reduced 25.2%	183,218 $1.4 Million
Q4 2023 Feb 14, 2024	BUY	$2.71 - $4.5 $242,878 - $403,303	89,623 Added 57.71%	244,928 $1.04 Million
Q2 2023 Aug 14, 2023	BUY	$4.93 - $6.74 $765,653 - $1.05 Million	155,305 New	155,305 $865 Million
Q1 2023 May 15, 2023	BUY	$1.3 - $5.73 $9,140 - $40,287	7,031 Added 5.0%	147,654 $846,000
Q4 2022 Feb 14, 2023	SELL	$1.05 - $2.82 $26,118 - $70,147	-24,875 Reduced 15.03%	140,623 $0
Q3 2022 Nov 14, 2022	SELL	$2.57 - $5.45 $15,031 - $31,877	-5,849 Reduced 3.41%	165,498 $444 Million
Q2 2022 Aug 12, 2022	BUY	$3.2 - $5.96 $548,310 - $1.02 Million	171,347 New	171,347 $817,000

Others Institutions Holding INZY

# of Institutions

Shares Held

52.4M

Call Options Held

17.6K

Put Options Held

2.7K

Adage Capital Partners Gp, L.L.C. Boston, MA

5.73M
Shares

$29.4 Million
0.05% of portfolio
Pivotal Bio Venture Partners Investment Advisor LLC San Francisco, CA

4.49M
Shares

$23.1 Million
18.06% of portfolio
Sofinnova Investments, Inc. Menlo Park, CA

4.28M
Shares

$22 Million
1.06% of portfolio
Eventide Asset Management, LLC Boston, MA

3.94M
Shares

$20.2 Million
0.31% of portfolio
Rock Springs Capital Management LP Baltimore, MD

3.7M
Shares

$19 Million
0.51% of portfolio

View Full List

About Inozyme Pharma, Inc.

Ticker INZY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,145,700
Market Cap $206M
Description
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, ...

More about INZY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Oconnor LLC with notifications on news.

Account